Ozempic and Wegovy maker Novo Nordisk quieted Wall Street's concerns with its fourth-quarter results and 2025 outlook.

U.S. stocks were mixed and benchmark Treasury yields slid on Wednesday as disappointing earnings and mixed economic data ...

In its outlook for 2025, Novo Nordisk has predicted 'continued periodic supply constraints and related drug shortage ...